On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Skinvisible, Inc. (SKVI) Aims to Increase Shareholder Value through Proposed Deal with Quoin

  • Drug delivery platform ideal for M&A-driven growth
  • $80 billion global dermatology market
  • $30 billion global over-the-counter skincare market
  • Half of the 100 million surgeries performed in the U.S. require post-surgical pain medication, according to Transparency Market Research report

If history repeats itself, as we are often told, then Skinvisible, Inc.’s (OTCQB: SKVI) proposed deal with Quoin Pharmaceuticals Limited (“Quoin”) could increase shareholder value after execution. In late 2017, the company announced its plan to merge with Quoin, a marriage made in heaven that combines Skinvisible’s virtues as a drug delivery developer with Quoin’s position as a producer of post-surgical pain products that replace or diminish opioid use (http://cnw.fm/Fi2E7). Over the past two decades, mergers in the pharmaceutical industry have generally resulted in positive returns to shareholders, and today’s market leaders are the ones that have been most active in mergers and acquisitions.

There are many reasons why a merger may make sense. Taking over a rival, for example, means acquiring that rival’s market share and most, if not all, of its revenues. If product lines or business divisions overlap, costs can be cut and synergies exploited. In addition, purchasing a rival or merging with one may mean the acquisition of exciting new products at a much-reduced cost. It may cost the acquirer less to buy the target (and its product line) than to attempt to develop similar products in-house. Also, borrowing costs matter. If interest rates are low and likely to rise, now might be the time to borrow and spend. These are all good rationales for corporate consolidations. However, ‘growth is the main driver for most M&A deals: not just growth in drug distribution scale or earnings growth through cost cutting, but in revenues—and especially share price’, according to McKinsey & Company (http://cnw.fm/6WkAw).

Skinvisible is ideally poised to grow by acquisition, since its core business revolves around a drug delivery methodology that’s applicable to a wide range of topical products. Such ‘platform companies’ have a bright future, since they are enablers rather than competitors to other drug companies. Hedge fund manager Bill Ackman, the founder of Pershing Square Capital Management, opined, ‘“platform companies”—those that grow through bolt-on acquisitions—enrich their shareholders with each new deal…’ (http://cnw.fm/M9tG1). If that is to be believed, there’s little doubt that Skinvisible is treading the right path.

Since 1999, pharmaceutical and cosmeceutical companies have been adopting Skinvisible’s Invisicare® technology, developed through wholly-owned subsidiary Skinvisible Pharmaceuticals, Inc. The technology can be used to revitalize or create new medical or skincare products, allowing a company that licenses Skinvisible’s formulations to sell its own patented product and combat generic competitors.

Products utilizing Invisicare have been effective at bonding active ingredients to the skin for up to four hours and longer. Invisicare is non-occlusive; it allows normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. When topically applied, products formulated with Invisicare adhere to the skin’s outer layers, forming a protective bond, resisting wash-off and delivering targeted levels of therapeutic or cosmetic skincare agents to the skin. This allows enhanced delivery performance for a variety of topicals resulting in improved efficacy, longer duration of action, reduced irritation and lower dosage of active agents required. The ‘invisible’ polymer compositions that make up Invisicare wear off as part of the natural exfoliation process that removes the skin’s outer layer of cells.

With a $80 billion global dermatology market and a $30 billion global over-the-counter skincare market, the patented polymer delivery system for topical products developed by Skinvisible has a great deal of potential to add shareholder value.

For more information, visit the company’s website at www.Skinvisible.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Archives

Select A Month

Official NewsWire Relationships

Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition Cannexpo Marigold PR MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo Tether BudTender Tether BudTender Appreciation Week

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722